Payment overview · 2025
General Payments
$92.28
5 reported records · 2 companies
Healthcare provider profile · identity verified
Royce K Bailey, MD, MPH
Allopathic & Osteopathic Physicians|Internal Medicine · HENDERSONVILLE, NC · NPI 1518961853
Verified facts
What the public records show
CMS Open Payments records show Royce K Bailey, MD, MPH received $92.28 in general payments during 2025 across 5 reported records.
Novartis Pharmaceuticals Corporation accounted for 62.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $57.85 | 62.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.43 | 37.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $92.28 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $24.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 602 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 79 |
| Lisinopril | Lisinopril | 267 | 76 |
| Losartan Potassium | Losartan Potassium | 254 | 78 |
| Gabapentin | Gabapentin | 244 | 60 |
| Prednisone | Prednisone | 223 | 91 |
| Omeprazole | Omeprazole | 209 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 49 |
| Lorazepam | Lorazepam | 201 | 49 |
| Azithromycin | Azithromycin | 189 | 103 |
| Furosemide | Furosemide | 186 | 69 |
| Cephalexin | Cephalexin | 175 | 84 |
| Xarelto | Rivaroxaban | 160 | 37 |
| Eliquis | Apixaban | 149 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 49 |
| Trazodone Hcl | Trazodone Hcl | 138 | 38 |
| Alprazolam | Alprazolam | 125 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 35 |
| Simvastatin | Simvastatin | 121 | 37 |
| Metformin Hcl | Metformin Hcl | 119 | 35 |
| Allopurinol | Allopurinol | 117 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 44 |
| Spironolactone | Spironolactone | 114 | 36 |
| Pregabalin | Pregabalin | 110 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 29 |
| Jardiance | Empagliflozin | 104 | 19 |
| Fluconazole | Fluconazole | 101 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 21 |
| Tramadol Hcl | Tramadol Hcl | 90 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 30 |
| Potassium Chloride | Potassium Chloride | 84 | 25 |
| Clonazepam | Clonazepam | 81 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 13 |
| Sertraline Hcl | Sertraline Hcl | 68 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 24 |
| Bupropion Xl | Bupropion Hcl | 64 | 16 |
| Atenolol | Atenolol | 63 | 18 |
| Bumetanide | Bumetanide | 62 | 20 |
| Famotidine | Famotidine | 61 | 27 |
| Clonidine Hcl | Clonidine Hcl | 60 | 12 |
| Montelukast Sodium | Montelukast Sodium | 60 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Carvedilol | Carvedilol | 59 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 23 |
| Celecoxib | Celecoxib | 57 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 55 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 11 |
| Mirtazapine | Mirtazapine | 51 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 50 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 18 |
| Diazepam | Diazepam | 49 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 12 |
| Temazepam | Temazepam | 49 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | 11 |
| Methocarbamol | Methocarbamol | 48 | 18 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 18 |
| Glimepiride | Glimepiride | 45 | 15 |
| Meloxicam | Meloxicam | 44 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 13 |
| Hydrocortisone | Hydrocortisone | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | 13 |
| Armour Thyroid | Thyroid,pork | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Pentoxifylline | Pentoxifylline | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 16 |
| Metronidazole | Metronidazole | 32 | 23 |
| Digoxin | Digoxin | 31 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 15 |
| Nystatin | Nystatin | 31 | 18 |
| Baclofen | Baclofen | 30 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Finasteride | Finasteride | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Np Thyroid | Thyroid,pork | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Probenecid | Probenecid | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 11 |
| Methylphenidate Er | Methylphenidate Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 11 |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | 12 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.28 · 5 records | Novartis Pharmaceuticals Corporation | KISQALI, Kerendia, LEQVIO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error